Jove
Visualize
Contact Us

Related Experiment Videos

Continuous antigenic stimulation system (CASS) as a new immunization strategy.

Andrew Gomez-Vargas1, Kenneth L Rosenthal, Mark R McDermott

  • 1Department of Pathology and Molecular Medicine, McMaster University Health Sciences Centre, Hamilton, Ont., Canada L8N 3Z5.

Vaccine
|September 15, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chitosan-DNA nanoparticles: synthesis and optimization for long-term storage and effective delivery.

PeerJ·2025
Same author

In vitro and in vivo toxicity of thiolated and PEGylated organosilica nanoparticles.

International journal of pharmaceutics·2024
Same author

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice.

Scientific reports·2022
Same author

Sustained Delivery of a Monoclonal Antibody against SARS-CoV-2 by Microencapsulated Cells: A Proof-of-Concept Study.

Pharmaceutics·2022
Same author

High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination.

PloS one·2022
Same author

Mesenchymal Stem Cells Coated with Synthetic Bone-Targeting Polymers Enhance Osteoporotic Bone Fracture Regeneration.

Bioengineering (Basel, Switzerland)·2020
Same journal

Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" [Vaccine 82 (2026) 128588].

Vaccine·2026
Same journal

Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR.

Vaccine·2026
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

A novel immunization strategy using encapsulated cells secreting human factor IX (hFIX) in mice induced a sustained immune response. This continuous antigenic stimulation system (CASS) shows potential for developing new vaccines.

Area of Science:

  • Immunology
  • Biotechnology
  • Vaccinology

Background:

  • Sustained immune responses are crucial for disease protection.
  • Traditional immunization methods have limitations in eliciting long-lasting immunity.

Purpose of the Study:

  • To introduce a novel immunization strategy called continuous antigenic stimulation system (CASS).
  • To evaluate the immunogenicity and durability of CASS using encapsulated cells secreting human factor IX (hFIX) in a mouse model.

Main Methods:

  • Mice were implanted with encapsulated C2C12 myoblasts engineered to secrete hFIX.
  • Humoral and cellular immune responses were assessed and compared to traditional adjuvant-based immunization.
  • Key immune markers including antibody titers (IgG2a) and cytotoxic T lymphocyte (CTL) activity were measured.

Related Experiment Videos

Main Results:

  • Encapsulated cell implantation elicited a robust humoral immune response against hFIX, surpassing that of complete Freund's adjuvant (FA).
  • A significant increase in IgG2a antibody titers indicated a shift towards a Th1-polarized immune response.
  • Strong and sustained hFIX-specific CTLs were detected for up to 213 days post-implantation.

Conclusions:

  • The continuous antigenic stimulation system (CASS) represents a novel and effective immunization strategy.
  • Encapsulated cells secreting therapeutic proteins can induce durable cellular and humoral immunity.
  • CASS holds promise for the development of next-generation vaccines offering long-lasting protection.